Breast cancer has become the most common malignant tumor in the world. Among them, human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for 15%-20%. It is highly malignant and easy to relapse and metastasis in a short time, and is considered as one of the most aggressive types of breast cancer. But with the advent of anti-HER2-targeting drugs, survival has been improved significantly in HER2-positive patients. At present, common anti-HER2 drugs include monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and antique-drug conjugates (ADCs). In terms of treatment options, trastuzumab combined with chemotherapy is the basis for the treatment of HER2-positive breast cancer. Early stage patients with high risk factors can further strengthen targeted therapy to improve prognosis, while advanced patients need to rationally select the appropriate strategy of targeted therapy according to different conditions to achieve longer survival.